About: Alnylam Pharmaceuticals

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Alnylam Pharmaceuticals Goto Sponge NotDistinct Permalink

An Entity of Type : umbel-rc:Business, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FAlnylam_Pharmaceuticals&invfp=IFP_OFF&sas=SAME_AS_OFF

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Attributes	Values
rdf:type	Thing company schema:Organization dul:Agent dul:SocialPerson agent wikidata:Q24229398 Organization Business enterprise yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates umbel-rc:Business
rdfs:label	Alnylam Pharmaceuticals (de) Alnylam Pharmaceuticals (en) 艾拉倫 (zh) Alnylam Pharmaceuticals (uk)
rdfs:comment	Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (en) Alnylam Pharmaceuticals ist ein US-amerikanisches, medizinisches Forschungsunternehmen, das 2002 gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen ALNY gelistet ist. Alnylam hat seinen Hauptsitz in Cambridge, MA. Die europäische Zentrale befindet sich in Maidenhead, UK. und die deutsche Niederlassung in München. Das Unternehmen macht sich die Entdeckung der RNA-Interferenz der beiden Nobelpreisträger Andrew Z. Fire und Craig C. Mello zunutze. Mit-Gründer des Unternehmens sind der Nobelpreisträger Phillip Allen Sharp und der Deutsche Thomas Tuschl, der einen wesentlichen Anteil an der Entdeckung der RNA-Interferenz in Säugetierzellen hatte. Alnylam ist eine Ausgründung aus dem Max-Planck-Institut für biophysikalische Chemie. (de) Alnylam Pharmaceuticals Inc. — біофармацевтична компанія, яка зосереджена на відкритті, розробці та комерціалізації терапії РНК-інтерференцією (RNAi) для генетичних захворювань. Компанію було засновано в 2002 році, її штаб-квартира знаходиться в Кембриджі, штат Массачусетс . У 2016 році Forbes включив компанію до списку «100 найбільш інноваційних компаній, що розвиваються». (uk) 艾拉倫是一家生物製藥公司，致力於發現、開發與應用「RNAi核醣核酸干擾機轉」治療遺傳性疾病。艾拉倫成立於2002年，總部位於美國麻塞諸塞州劍橋市，2016年曾入圍富比士「100家最具創新力的成長型公司」名單。 (zh)
foaf:name	Alnylam Pharmaceuticals, Inc. (en)
name	Alnylam Pharmaceuticals, Inc. (en)
foaf:depiction
sec cik	1178670 (xsd:integer)
dcterms:subject	Therapeutic gene modulation 2002 establishments in Massachusetts Biotechnology companies of the United States Companies listed on the Nasdaq Companies based in Cambridge, Massachusetts 2004 initial public offerings Biopharmaceutical companies Health care companies based in Massachusetts Pharmaceutical companies of the United States Biotechnology companies established in 2002 Pharmaceutical companies established in 2002
Wikipage page ID	40448087 (xsd:integer)
Wikipage revision ID	1106784286 (xsd:integer)
Link from a Wikipage to another Wikipage	Cambridge, Massachusetts MicroRNA David Bartel Therapeutic gene modulation Hoffmann-La Roche Huntington's disease Patisiran Paul Schimmel RNA interference Public company Neurodegeneration 2002 establishments in Massachusetts Biotechnology companies of the United States Companies listed on the Nasdaq dbr:Amyloid-beta_precursor_protein Max Planck Institute for Biophysical Chemistry Medicines and Healthcare products Regulatory Agency Medtronic Regulus Therapeutics Genzyme GlaxoSmithKline Monsanto NASDAQ Thomas Tuschl Pharmaceutical industry Progressive multifocal leukoencephalopathy Companies based in Cambridge, Massachusetts Alnilam Cubist Pharmaceuticals Alzheimer's disease Forbes Norton, Massachusetts Biogen Idec Familial amyloid neuropathy Ionis Pharmaceuticals Transthyretin-related hereditary amyloidosis 2004 initial public offerings Biopharmaceutical companies Health care companies based in Massachusetts Pharmaceutical companies of the United States Biotechnology companies established in 2002 Pharmaceutical companies established in 2002 John Maraganore Biopharmaceutical CHDI Foundation Yvonne Greenstreet Initial public offering Kyowa Hakko Kirin Merck & Co. Olivier Brandicourt Orion (constellation) Cerebral amyloid angiopathy Christoph Westphal

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software